Tofacitinib in antisynthetase syndrome-related rapidly progressive interstitial lung disease

Rheumatology (Oxford). 2020 Dec 1;59(12):e142-e143. doi: 10.1093/rheumatology/keaa323.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Disease Progression
  • Humans
  • Lung Diseases, Interstitial / drug therapy*
  • Lung Diseases, Interstitial / etiology
  • Male
  • Middle Aged
  • Myositis / complications
  • Piperidines / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Time Factors

Substances

  • Piperidines
  • Pyrimidines
  • tofacitinib

Supplementary concepts

  • Antisynthetase syndrome